Juliane Walz
@julianewalz
ID: 1285290331026657280
20-07-2020 19:08:01
46 Tweet
68 Followers
25 Following
Die Uniklinik Universität Tübingen hat einen #Corona - #Impfstoff speziell für Patienten mit Antikörpermangel entwickelt. Er zielt auf die Stimulierung e. zellulären Immunantwort durch T-Zellen sowohl gegen das Spike-Protein, als auch zahlr. andere Virusbestandteile. ow.ly/SEoX50FeTm4
The Schering Stiftung is honored to award the #FriedmundNeumannPrize2021 to #JudithFeucht for her contributions to developing and implementing T cell therapies to improve clinical care for cancer patients. Congratulations! Uniklinikum Tübingen Visualizing and Targeting Cancer Stress
Our latest publication in Cancer Discovery (Cancer Discovery) reporting on T-cell responses to #SARSCoV2 in #cancer patients. cancerdiscovery.aacrjournals.org/content/candis…
From the August issue: Pre-existing and post-#COVID19 immune responses to #SARS-CoV-2 in patients with cancer. bit.ly/3zojRyl Dr. Tatjana Bilich🇺🇦 @mroerden Juliane Walz Peptide-based Immunotherapy Uniklinikum Tübingen Visualizing and Targeting Cancer Stress Universität Tübingen
CTI Original: ‘Landscape of T-cell repertoires with public #COVID-19-associated TCRs in pre-pandemic risk cohorts’ @DonjeteS BinderLab Malte Mohme Peptide-based Immunotherapy Yu Zhao yacine.maringer Peptide-based Immunotherapy Sandra Ciesek UKE Hamburg onlinelibrary.wiley.com/doi/full/10.10… #ClinTransImmunol #CTICOVIDCollection
Did you know Peptide-based Immunotherapy Visualizing and Targeting Cancer Stress develops specific #covid19 #vaccine for #cancer patients? this is why youtu.be/qhtemtOV8Z0
Check out our new publication European Journal of Immunology about #SARSCoV2 reactive T-cell receptors! Peptide-based Immunotherapy Mat. onlinelibrary.wiley.com/doi/10.1002/ej…
Wir suchen nach studentischer Verstärkung bei der Aufarbeitung von Patienten-Proben! Bei Interesse an einer HiWi-Stelle und mehr Infos gerne eine Mail an [email protected] senden.
Our clinical peptide vaccine study against chronic lymphocytic #Leukemia is recruiting successfully. It is now also open for #CLL patients treated with novel BTK inhibitor Acalabrutinib. For more information visit medizin.uni-tuebingen.de/de/immuntherap… or contact [email protected]
A great immunopeptidomics update for the Prosit tool published in Nature Communications nature.com/articles/s4146…
3 exciting presentations by our lab members in the #immunotherapy session today DGHO e. V.
Within the iFIT Early Career program, a #poster session took place during our iFIT Retreat. #Congratulations to our winners for their outstanding #research which convinced our jury! 1st place: Clemens Hinterleitner, shared 2nd place: Martina Giampetraglia & Björn Traenkle. #cancerresearch
Good review by Bertoletti Lab on the importance of #SARSCoV2-specific #tcells after vaccination and infection in Cellular and Molecular Immunology nature.com/articles/s4142…
